

USSN.: 09/554,533
Atty. Docket No. 238/086 US**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

BEELY, Nigel R.A., et al.

Appln. No.: 09/554,533

371 Filing Date: 11 July 2002

For: *Novel Exendin Agonist Compounds*

Art Unit: 1656

Examiner: LIU, Samuel W.

Atty. Docket: 238/086 US

Confirm. No.: 1938


United States Patent and Trademark Office
Commissioner for Patents
Box Issue Fee
Washington, D.C. 20231**FACSIMILE TRANSMITTAL COVER SHEET****Certificate of Transmission Under 37 C.F.R. 1.8**

The following documents are being submitted via facsimile transmittal in response to the Notice of Allowance and Fee(s) Due, mailed March 7, 2007:

<u>Documents(s)</u>	<u>No. of Pages</u>
Part B - Fee(s) Transmittal (in duplicate for fees)	2
Notification of Loss of Small Entity Status	1
Amendment under 37 C.F.R. 1.312	5
<i>Facsimile Cover Sheet</i>	1
Total Pages	9

Should any other fee become due or credit become payable during the pendency of these proceedings, the Commissioner is authorized to charge or credit the same to Deposit Account Number 010535.

I hereby certify that the following listed correspondence in the above-referenced application is being transmitted by facsimile to the Commissioner for Patents, Alexandria, VA to facsimile (571) 273-2885 on Wednesday, April 04, 2007.


Kelly B. Solomon

USSN.: 09/554,533
Atty. Docket No. 238/086 USIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

BEBLY, Nigel R.A., et al.

Appln. No.: 09/554,533

371 Filing Date: 11 July 2002

For: *Novel Exendin Agonist Compounds*

Art Unit: 1656

Examiner: LIU, Samuel W.

Atty. Docket: 238/086 US

Confirm. No.: 1938

NOTIFICATION OF LOSS OF SMALL ENTITY STATUSBox Issue Fee
Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR 1.27(g)(2), the undersigned hereby notifies the U.S. Patent and Trademark Office of loss of entitlement to small entity status. This notification is being submitted at the time of paying the earliest of an issue fee or a maintenance fee due after the date on which status as a small entity, as defined in 37 CFR 1.27(a), is no longer appropriate. This notification is signed by an appropriate party, as identified in 37 CFR 1.33(b).

The undersigned believes that the appropriate fee is enclosed or authorization has been given to charge the deposit account. However, in the event any additional fees are due or any amount is to be credited, the undersigned authorizes the Commissioner of Patents to debit or credit Deposit Account No. 010535.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

Dated: 4-Apr-07By: Dianne Rees

Dianne Rees, Ph.D.

Registration No. 45,281

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Telephone: 858.552.2200
Facsimile: 858.552.1936